Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA: SCB-2019 Vaccine for COVID-19 Prevention
NCT04672395Phase 3Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Mar 2021
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of SCB-2019 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Number of Participants with a First Occurrence of COVID-19 of Any Severity, Number of Participants with Solicited Local and Systemic Adverse Reactions and 3 more. Started Mar 2021; status: completed.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04672395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672395.